Summary & Overview
HCPCS G9130: Multiple Myeloma Disease Status Assessment
HCPCS Level II code G9130 represents an oncology service for documenting disease status in patients with multiple myeloma or systemic disease when the extent of disease is unknown, staging is in progress, or not listed. The code is designated for use within Medicare-approved demonstration projects and captures assessments related to staging and initial disease-status determination. Nationally, this code matters because it facilitates standardized reporting of complex staging situations in demonstration contexts and can influence how demonstration projects measure diagnostic workflows for hematologic malignancy care.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines how payers approach coverage and coding recognition in demonstration settings and highlights the administrative context that accompanies a HCPCS Level II demonstration-only code.
Readers will learn the clinical context for use of G9130, the typical service locations where it is applied (hospital outpatient departments and oncology clinics), and the practical implications for billing within Medicare demonstration projects. The report also summarizes available benchmarks and policy considerations relevant to demonstration coding, describes common modifiers used with HCPCS Level II codes, and notes where input data were not provided. Data not available in the input are identified where appropriate.
Billing Code Overview
HCPCS Level II code G9130 denotes a service in oncology focused on disease status assessment for patients with multiple myeloma or systemic disease when the extent of disease is unknown, staging is in progress, or not listed. The code is specified for use in a Medicare-approved demonstration project.
-
Service type: Oncology disease status assessment, limited to staging/assessment activities related to multiple myeloma or systemic disease where extent is unknown or pending
-
Typical site of service: Hospital outpatient departments, oncology clinics, or other ambulatory care settings where staging and disease-status evaluations are performed as part of a demonstration project
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with newly suspected multiple myeloma is referred to a Medicare-approved oncology demonstration program for baseline disease status assessment. The patient presents with fatigue, anemia, back pain, and elevated serum protein on routine labs. The oncology team schedules a comprehensive evaluation to determine extent of disease while staging studies are pending. The clinical workflow includes an initial clinic visit with hematology/oncology, review of prior records, targeted physical exam, laboratory tests (CBC, CMP, serum and urine protein electrophoresis, free light chains), bone marrow biopsy scheduling, and imaging orders (skeletal survey, whole-body low-dose CT or PET/CT as indicated). Documentation of the reason for disease status assessment and the limited scope specific to multiple myeloma is recorded. The billing code G9130 is used to report oncology disease status assessment limited to multiple myeloma when extent of disease is unknown, staging is in progress, or not listed, within the parameters of the Medicare demonstration project. Typical site of service is an outpatient oncology clinic, hospital outpatient department, or an academic cancer center participating in the demonstration. Typical patient scenario includes coordination of staging studies, communication with referring provider, and planning for initiation of myeloma-directed therapy pending confirmation of disease extent and final staging.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |